Literature DB >> 9169752

Temperature-sensitive mutants of Actinobacillus pleuropneumoniae induce protection in mice.

W Byrd1, A M Hooke.   

Abstract

Temperature-sensitive mutants of Actinobacillus pleuropneumoniae 4074, serotype 1, were isolated after treatment with nitrosoguanidine and enrichment with penicillin and D-cycloserine. Of the four temperature-sensitive mutants evaluated in mice, one (A-1) had a tight phenotype (i.e., it ceased replication immediately after transfer to the nonpermissive temperature [37 degrees C]) and three (1-2, 4-1, and 12-1) were coasters that continued replication for up to three generations after transfer to 37 degrees C. The reversion frequencies ranged from 10(-6) to 10(-9), and cutoff temperatures ranged from 33 to 35 degrees C. No major changes were detected in the biochemical profiles; agglutination reactions; electrophoretic profiles of the lipopolysaccharides, outer membrane proteins, and hemolysin proteins; hemolytic titers; or CAMP factor reactions of the mutants and the wild-type bacteria. Groups of 3- to 5-week-old, female ICR mice were immunized intranasally with three doses of 3.5 x 10(6) CFU of the mutants over 3 weeks and subsequently challenged intranasally with 5 50% lethal doses of the parental wild-type. Protection was induced by both the tight and the coaster mutants, with the 4-1 and 12-1 coasters eliciting greater protection (67 and 82%, respectively) than that induced by the A-1 tight mutant (57%). Intranasal immunization with both phenotypes induced serum antibody responses against the surface antigens and the hemolysin protein.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169752      PMCID: PMC175304          DOI: 10.1128/iai.65.6.2206-2210.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Oral immunization against experimental salmonellosis I. Development of temperature-sensitive mutant vaccines.

Authors:  K J Fahey; G N Cooper
Journal:  Infect Immun       Date:  1970-03       Impact factor: 3.441

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Purification, characterization and immunological properties of the serotype-specific capsular polysaccharide of Pasteurella haemolytica (serotype A1) organisms.

Authors:  C Adlam; J M Knights; A Mugridge; J C Lindon; P R Baker; J E Beesley; B Spacey; G R Craig; L K Nagy
Journal:  J Gen Microbiol       Date:  1984-09

4.  Preparation, characterization, and immunogenicity of conjugate vaccines directed against Actinobacillus pleuropneumoniae virulence determinants.

Authors:  W Byrd; S Kadis
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

5.  Growth and hemolysin production by Haemophilus pleuropneumoniae cultivated in a chemically defined medium.

Authors:  J R Maudsley; S Kadis
Journal:  Can J Microbiol       Date:  1986-10       Impact factor: 2.419

6.  The serological properties of the cell surface proteins of Vibrio cholerae.

Authors:  S Kabir
Journal:  J Gen Microbiol       Date:  1983-07

7.  Temperature-sensitive mutants of Pseudomonas aeruginosa: isolation and preliminary immunological evaluation.

Authors:  A M Hooke; P J Arroyo; M P Oeschger; J A Bellanti
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

8.  Characterization of a non-hemolytic mutant of Actinobacillus pleuropneumoniae serotype 5: role of the 110 kilodalton hemolysin in virulence and immunoprotection.

Authors:  T J Inzana; J Todd; J N Ma; H Veit
Journal:  Microb Pathog       Date:  1991-04       Impact factor: 3.738

9.  Haemophilus parahaemolyticus serotypes. Pathogenicity and cross immunity.

Authors:  R Nielsen
Journal:  Nord Vet Med       Date:  1979-10

10.  Evaluation of a Killed Vaccine Against Porcine Pleuropneumonia Due to Haemophilus pleuropneumoniae.

Authors:  R Higgins; S Larivière; K R Mittal; G P Martineau; P Rousseau; J Cameron
Journal:  Can Vet J       Date:  1985-02       Impact factor: 1.008

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.